scholarly journals Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (rcc)

2017 ◽  
Vol 28 ◽  
pp. v307-v308
Author(s):  
T. Powles ◽  
R.J. Motzer ◽  
D.J. George ◽  
E. Jonasch ◽  
S. Pal ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Phase 3 ◽  
Plasma Biomarkers

scholarly journals Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Thomas Powles ◽  
Toni K. Choueiri ◽  
Robert J. Motzer ◽  
Eric Jonasch ◽  
Sumanta Pal ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Phase 3 ◽  
Plasma Biomarkers

TIVO-3: A Phase 3, Randomised, Open-Label Study Comparing Tivozanib to Sorafenib in Patients with Advanced Renal Cell Carcinoma

2019 ◽  
Author(s):  
Brian Rini ◽  
Sumanta K. Pal ◽  
Bernard J. Escudier ◽  
Michael B. Atkins ◽  
Thomas E. Hutson ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Study ◽  
Label Study

scholarly journals Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma

Kidney Cancer ◽  
2020 ◽  
Vol 4 (1) ◽  
pp. 29-39
Author(s):  
Nizar M. Tannir ◽  
Thomas Powles ◽  
Bernard Escudier ◽  
Frede Donskov ◽  
Viktor Grünwald ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Clinical Outcomes ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Phase 3

scholarly journals Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial

2020 ◽  
Vol 26 (11) ◽  
pp. 1733-1741 ◽  
Author(s):  
Robert J. Motzer ◽  
Paul B. Robbins ◽  
Thomas Powles ◽  
Laurence Albiges ◽  
John B. Haanen ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Phase 3 ◽  
Biomarker Analysis

scholarly journals Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma

2018 ◽  
Vol 119 (6) ◽  
pp. 663-669 ◽  
Author(s):  
Thomas Powles ◽  
Robert J. Motzer ◽  
Bernard Escudier ◽  
Sumanta Pal ◽  
Christian Kollmannsberger ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Phase 3 ◽  
Prior Therapy
Sign in / Sign up

Export Citation Format

Share Document